Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Kraft Heinz Co (KHC) vs BIO-TECHNE Corp (TECH) Price & Performance

Kraft Heinz CoTrade
BIO-TECHNE CorpTrade

Price performance (Past 24H)

Key statistics

Kraft Heinz Co vs BIO-TECHNE Corp — how do they compare? Kraft Heinz Co trades at $22.27 (market cap $26.66B), while BIO-TECHNE Corp trades at $72.5 (market cap $11.36B). The key difference: Kraft Heinz Co is far larger — about 2.3× BIO-TECHNE Corp's market cap, and Kraft Heinz Co pays the higher dividend (7.12%). Which is the better fit depends on your goals — on Pluang, investors hold Kraft Heinz Co for 129 Days and BIO-TECHNE Corp for 64 Days on average.

KHCTECH
Market Cap
$26.66B$11.36B
Volume
31,300,1095,390,331
Sector
Consumer StaplesHealth
52-Week High
$27.62$72.61
52-Week Low
$21.21$43.31
Typical Hold Time
129 Days64 Days
Enterprise Value
$42.98B$11.39B
Dividend Yield
7.12%0.44%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Kraft Heinz Co

Kraft Heinz (KHC) trades at $22.08, up 0.45% on the day, with a bearish technical outlook despite recent earnings beats. The stock shows mixed signals with a low P/E of 13.04 and P/B of 0.74, but negative profitability metrics including a net income margin of -13.64% and ROE of -8.78% reflect challenges from a recent $5.85B net loss in 2025. The company maintains strong operating cash flow of $4.46B and a dividend yield near 6.5%, supported by ongoing brand reinvestment efforts.

The investment outlook is cautious; valuation discounts may attract value investors, but persistent volume declines and high debt pose significant risks. Analyst consensus is mixed with a $24.50 price target, yet only 11.43% recommend buying. Key catalysts include successful turnaround execution and new product launches, though competitive pressures and margin recovery remain critical hurdles for sustained shareholder value.

BIO-TECHNE Corp

Bio-Techne (TECH) trades at $72.45, down 0.11% on the day, near its 52-week high of $72.70. The stock shows bullish technical signals with strong moving average support. Fundamentally, the company maintains solid gross margins of 65.77% but faces declining net income margins, dropping from 24.6% in 2022 to 6.01% in 2025. Recent shareholder approval of Merck KGaA's acquisition at $73 per share provides a clear near-term catalyst.

The pending acquisition offers limited upside from current levels but provides downside protection. However, declining profitability trends and elevated valuation ratios (P/E 62.46) pose risks if the deal falls through. Investors should weigh the acquisition premium against fundamental deterioration in earnings quality.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

KHC
100% Buy0% Sell
Avg holding period · 129 Days
TECH

No sentiment data available yet.

Top news

Latest headlines on both assets

About Kraft Heinz Co

In July 2015, Kraft merged with Heinz to create the third-largest food and beverage manufacturer in North America behind PepsiCo and Nestle and the fifth-largest player in the world. Beyond its namesake brands, the combined firm's portfolio includes Oscar Mayer, Velveeta, and Philadelphia. Outside North America, the firm's global reach includes a distribution network in Europe and emerging markets that drive around one fifth of its consolidated sales base, as its products are sold in more than 190 countries and territories.

Read more on KHC →

About BIO-TECHNE Corp

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.

Read more on TECH →